ABSTRACT The fibrinolytic enzyme from southern copperhead snake venom, fibrolase, contains 1 mole of zinc per mole of protein, belongs to the major family of metalloproteinases known as the metzincins, and has been shown to degrade fibrin clots in vitro and in vivo. The purpose of this study was to develop a 3-dimensional model of fibrolase to investigate the geometry of conserved and variable sequences between members of the snake venom metalloproteinases. When compared to atrolysin C (form D) or adamalysin II (metzincins with completely different substrate specificity), fibrolase has approximately 60% overall sequence identity and nearly 100% sequence similarity in the active site. We used the crystal structure of adamalysin II to build a 3-dimensional homology model of fibrolase. Three disulfide bonds were constructed (the highly conserved disulfide bond was maintained from the adamalysin II structure and 2 new disulfide bonds were introduced between residues 158-182 and 160-165). We used Sculpt 2.5 and HyperChem 5.0 to "dock" a substrate fragment octapeptide (HTEKLVTS), and a water molecule into the active site cleft. We calculated the differential average homology profile for fibrolase compared to 8 hemorrhagic and 5 nonhemorrhagic metzincins. We then determined the sequence regions that might be responsible for their substrate specificity. Our 3-dimensional homology model shows that the variable sequences lie on the periphery of the identified active site region containing the His triangle; this indicates that substrate specificity may depend on surface residues that are not directly associated with the active site.
INTRODUCTION
Pharmacologic dissolution of an established thrombus has become an accepted therapeutic approach for many patients who develop thrombotic occlusive disease (1) . Intravenous infusion of plasminogen activators, including recombinant tissue plasminogen activator, urokinase, streptokinase, and anisoylated plasminogen streptokinase-activator complex, is effective in restoring blood flow in occluded arteries and veins (1, 2) . However, clinical application of plasminogen activators leads to activation of circulating plasminogen as well as fibrin-bound plasminogen within the thrombus. The widespread systemic activation of the fibrinolytic system leads to the depletion of α2-antiplasmin and generation of free plasmin that degrades several plasma proteins, including fibrinogen and factors V and VIII. There are other limitations to currently available therapy. A significant percentage (25%-30%) of patients with acute myocardial infarction are resistant to reperfusion within 90 minutes despite the use of the most potent thrombolytic agents or combinations (3) , and systemic fibrinogenolysis with accompanying bleeding is encountered frequently. Further, 10% to 30% of patients experience acute coronary reocclusion after thrombolytic therapy (4) . There is also a small but significant risk of neurological complications (5) , including stroke (6) and intracranial hemorrhage (7) . Additionally, there is concern about the rapidly acting plasma inhibitor of the tissue plasminogen activator PAI-1 (8) , which is significantly increased in myocardial infarction (9) , and may, with other factors, predispose patients to reinfarction (10) .
The limited efficacy and potentially life-threatening side effects of available thrombolytic agents remain a problem. Investigators have attempted to overcome these problems by enhancing thrombolytic activity and improving targeting to the clot. Despite these modifications, all current thrombolytic agents depend on the plasmin being generated through plasminogen activation. Thus, there is strong rationale for evaluating new agents that act by different mechanisms than available agents do.
Snake venoms, particularly those from North American pit vipers, contain direct-acting fibrinolytic proteinases (11) . Fibrolase is the fibrinolytic enzyme from southern copperhead venom (12) . Fibrolase is a nonglycosylated metalloproteinase with a molecular weight of 23 000; it contains 1 mole of zinc per mole of protein (13) . The enzyme has an isoelectric point of approximately pH 6.8. The amino acid sequence of fibrolase has been determined (14) , and the enzyme belongs to the major family of metalloproteinases known as the metzincins (15) . Fibrolase is a member of the large subfamily of snake venom metalloproteinases called the adamalysin subfamily. This subfamily was named for the first member of the family whose 3-dimensional structure was determined-adamalysin II from eastern diamondback rattlesnake venom (16) . Adamalysin II is a zinc metalloproteinase that degrades plasma serine proteinase inhibitors (SERPINS), such as antithrombin III and α1-antiproteinase, whereas fibrolase has no effect on these proteins (13) . Thus, adamalysin II's activity profile is quite different than that of fibrolase. The 3-dimensional structure of adamalysin II reveals that the binding site for the catalytically essential zinc contains 3 histidine residues that are in an identical sequence location in fibrolase. Further, a methionine turn, which forms a hydrophobic base for the 3 active site histidine residues, is in an identical location, relative to the zinc-binding site, in the 2 enzymes (17, 18) .
Fibrolase has been shown to degrade fibrin clots made from purified fibrinogen or from blood plasma (13) . Fibrolase represents one of the few highly effective fibrinolytic enzymes that is not a plasminogen activator; it acts directly on fibrin and, because it is a metalloproteinase, is not inhibited by serine proteinase inhibitors that interfere with plasminogen activatorbased thrombolytic agents (19) . Our earlier studies demonstrated conclusively that fibrolase is a directacting fibrinolytic enzyme that does not activate plasminogen; it acts by a completely different mechanism than the plasminogen activators (20, 21) . Degradation of purified human fibrin (and fibrinogen) by the fibrinolytic enzyme was examined (20, 21) ; it was found that fibrolase preferentially degrades the α-chain of fibrin. There is also total degradation of the β-chain, although at a somewhat slower rate. These findings clearly demonstrate that fibrolase acts directly on fibrin/fibrinogen and does not require any bloodborne intermediates in the reaction. We have also demonstrated that the recombinant enzyme is an effective thrombolytic agent in a canine reoccluding carotid arterial thrombosis model (22) . Thrombolysis was achieved rapidly and there was no evidence of hemorrhage at the site of infusion or in any organ site after necropsy. Recently, a novel chimeric form of fibrolase has been constructed that possesses both fibrinolytic and antiplatelet activity in vitro (23, 24) .
Understanding the structure of a putative clinical agent such as fibrolase allows modifications to the protein structure to construct a more effective or specific therapeutic agent. As Markland et al have shown, fibrolase can be used effectively in vivo to clear thrombi from the carotid artery (22) . Although fibrolase has been used for successful thrombolysis, it is effectively and rapidly cleared from the bloodstream by α 2 -macroglobulin. Modifying the interaction between fibrolase and this inhibitor will allow a longer interaction between fibrolase and the thrombus. Knowledge about structure of fibrolase is important to this type of endeavor because modifications can be designed that take advantage of structural features of fibrolase that will effect the interaction with the inhibitor but will not effect the thrombolytic activity.
It is interesting that, despite the lack of hemorrhaging in animals after thrombolytic therapy with fibrolase, the enzyme possesses approximately 60% amino acid sequence identity with atrolysin C (form D), a hemorrhagic metalloproteinase from western diamondback rattlesnake venom. Thus, despite extensive sequence identity and postulated 3-dimensional structural resemblance with hemorrhagic metalloproteinases, fibrolase does not induce hemorrhaging either in vitro (13) or in vivo (22) . An early hypothesis regarding 6 specific amino acids suggested to be responsible for inducing hemorrhagic activity (25) has been refuted by analysis of additional hemorrhagic proteins and comparison with adamalysin II (16, 26) . Fibrolase also possesses approximately 60% sequence identity with adamalysin II; however, we have shown that fibrolase does not degrade SERPINS such as α1-antiproteinase (13) . Therefore, there must be subtle differences in or near the active site or in binding site geometry between these closely related snake venom metalloproteinase members of the adamalysin family. Analysis of the sequence of fibrolase has been used to predict the major secondary structural features and the location of its ion binding sites (26) .
In view of the potential clinical interest in fibrolase and because of the available 3-dimensional structure for adamalysin II (16), we employed homology modeling to build a model of fibrolase based on the available coordinates for adamalysin II. Recently the X-ray structure analysis of the interaction of atrolysin C (form D) with an inhibitor (27) and the structure of acutolysin A and C were published (28) (29) (30) . We have also calculated the differential average homology profile for fibrolase compared to other fibrinolytic metzincins and fibrolase compared to other hemorrhagic metzincins. Our model has enabled us to examine the 3-dimensional location of residues around the active site and the zinc-binding site regions of these 3 enzymes to identify subtle changes that may account for their unique substrate preferences.
In this article we describe a 3-dimensional model of fibrolase based on the coordinates of adamalysin II. Fibrolase is a member of the 3-disulfide group of metalloproteinases within the adamalysin family. The structure of 3 members of this class-H2 proteinase, a nonhemorrhagic proteinase from Trimeresurus flavoviridis (31) and acutolysin A and C, which are hemorrhagic toxins from Agkistrodon acutus-have been solved. Because both adamalysin II and atrolysin C are members of the 2-disulfide group, the structure we have modeled represents a unique structural subclass, a fibrinolytic nonhemorrhagic metalloproteinase. HRTD_CROAT. 
MATERIALS AND METHODS

Multiple
Calculation of average homology profiles
The average homology of fibrolase and 5 hemorrhagic enzymes was compared to the average homology profile for fibrolase and 8 nonhemorrhagic enzymes using a custom software program ProteoToolbox developed by LabSoft Solutions (Los Alamitos, CA http://www.labsoft.com). From a set of prealigned sequences, the individual homology at each position in the amino acid sequence was calculated as the sum of the number of sequences with an amino acid identical to fibrolase divided by the total number of sequences -1. Using a window span of 7 amino acids (central residue ± 3 residues) the moving average homology profile was calculated and plotted for fibrolase compared to hemorrhagic and nonhemorrhagic enzymes. Finally, the differential average homology profile was calculated by subtracting the average homology profile for the fibrinolytic metzincins from the average homology profile for the hemorrhagic metzincins.
Fibrolase Model Construction
Adamalysin II, a metzincin protein with a very high degree of homology to fibrolase and with a known 3-dimensional structure, was selected for homology modeling. Final sequence alignment between fibrolase and adamalysin II shows 60% sequence homology; an additional 7% of the residues are conservative replacements ( Table 2 ). The X-ray crystallographic coordinates for adamalysin II were obtained from the Protein Data Bank (http://www.rcsb.org/pdb/, PDB ID 1IAG). The program MIDASPlus (University of California-San Francisco) (46) was used to "mutate" 40% of the adamalysin residues to those in the fibrolase sequence. These changes in sequence altered only the amino acid side chains; the backbone atoms were not altered and the side chain χ (chi) angles were preserved when possible. Because the X-ray coordinates and the fibrolase-adamalysin sequence alignment do not contain the first amino acid of fibrolase-GLN 1-HyperChem 5.0 (Hypercube Inc, Gainesville, FL) was used to construct the coordinates for the N terminal GLN residue.
Energy minimization using the molecular mechanics force field AMBER 4.01 (University of California San Francisco, CA) was applied to the crude structure until the change in total energy was less than 0.1% of the total energy per 100 steps. This structure was initially minimized with only 2 of the 3 possible disulfide bonds in place to optimize the starting structure. Next, the optimized structure was prepared for a final minimization using the proper disulfide bonding combinations as described by Kumasaka et 
Docking of the Peptide Substrate
We used Sculpt 2.5 (Interactive Simulations, Inc. San Diego, CA) to manually "dock" a substrate fragment octapeptide (HTEKLVTS) into the active site cleft. The substrate peptide was derived from the sequence of the α-chain of human fibrinogen (AA 410-417) (47) . The peptide bond is cleaved between LYS 413 and LEU 414. The proposed mechanism of catalytic activity relies on the essential GLU 144 of fibrolase, which acts as a general base and aids in polarizing a water molecule that is sandwiched between the zinc atom and the substrate carbonyl group of LYS 413. Starting from an extended conformation for the substrate peptide, the Sculpt force field was used to mold the peptide into the binding site to allow for the optimum orientation of hydrogen bonds between the enzyme and the substrate. The peptide was rotated so that the lysine amino group was pointing away from the center of the fibrolase enzyme in the direction of the surrounding water. The final substrate enzyme complex was subjected to geometry optimization using the AMBER force field (48) as implemented in HyperChem 5.0. Because of the qualitative nature of our docking method and our current lack of understanding of exact substrate-enzyme interactions, we chose to optimize the final complex in the absence of water. Future work may address a more detailed examination of the peptide docking issues.
RESULTS
Perhaps the only instance that protein tertiary structure can be predicted with reasonable reliability from an amino acid sequence is when there exists a homologous protein whose 3-dimensional structure is known. If 2 protein amino acid sequences are more than 25% to 30% identical, there is almost certainly a structural similarity (49) . Homologous proteins have similar conformations and so far there are no exceptions to this rule (50) . A total of 9 structure "superfold" families (whose members are unrelated by sequence and function) account for 36% of the entire structural database (46% of nonhomologous proteins) according to Orengo et al (49) . Table 2 presents an alignment of adamalysin II, fibrolase, and atrolysin-C form D. The 2 nonfibrinolytic proteins are identical to fibrolase in approximately 60% and similar to fibrolase in 7% to 8% of the 203 residues. Figure 1 shows the schematic backbone of a model of fibrolase derived from the X-ray crystallographic coordinates for adamalysin II (molecular graphics figures can be viewed online at: http://www-rcf.usc.edu/~bolger/fibrolase/index.html). Three histidines coordinated to a zinc atom dominate the active site of the metzincin enzymes.
The catalytic mechanism involves polarization of a bound water molecule by the zinc atom, transfer of a proton from water to GLU 144, and subsequent attack of the resulting hydroxide at the carbonyl carbon of a lysine in the substrate peptide (51). Amino acid positions 160 and 182 are both cysteines in fibrolase compared to arginine and aspartate (ASP), respectively, for adamalysin II and atrolysin C (form D). The presence of these 2 additional cysteines required that we build a third disulfide bond in the fibrolase model that does not appear in the X-ray structures of the 2 model enzymes. In addition to the highly conserved disulfide (C118-C198) that stabilizes the tertiary structure of the C-terminal α-helix, the second (C158-C182) and third (C160-C165) disulfides in fibrolase act to stabilize a loop that is present in both atrolysin hemorrhagic toxin D and adamalysin II. The loop in these 2 nonfibrinolytic enzymes is formed by a different disulfide (C158-C165). This loop lies distant from the active site and at first glance does not appear to impart any functionality to the molecule.
Average homology profiles were calculated as described in Methods by comparing fibrolase to a set of 5 nonhemorrhagic and 8 hemorrhagic metzincins (Tables 3 and 4 ). Figure 2A shows the average homology profile for these 2 sets of multiply aligned sequences. The black line is the average homology profile for fibrolase compared to 8 hemorrhagic enzymes. The red line is average homology profile for fibrolase compared to 5 nonhemorrhagic enzymes. To find regions of these enzymes that might account for the lack of hemorrhagic activity in fibrolase, one must find sequence regions for which the nonhemorrhagic proteins are highly homologous to fibrolase and the hemorrhagic proteins have low homology to fibrolase. Most of the sequence regions that are directly involved in the catalytic mechanism (eg, amino acids 140-150) are highly homologous in Table 3 . Multiple Sequence Alignment for the 6 Known Fibrinolytic nonhemorrhagic Eenzymes ADAM_CROAD  -QQNLPQRYIELVVVADRRVFMKYNSDLNIIRTRVHEIVNIINEFYRSLNIRVSLTDLEI  FIBR_AGKCO  -QQRFPQRYVQLVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIQFTLVGLEI  ATROX_CROAT  -QQNLSQRYIELVVVADHRVFMKYNSDLNIIRKRVHELVNTINGFYRSLNIDVSLTDLEI  HR2_TRIFL  -QQRFPQRYIELAIVVDHGMYKKYNQNSDKIKVRVHQMVNHINEMYRPLNIAISLNRLQI  NEUW_BOTNE  QQRFFPQRYIELVIVADRRMYTKYNSDSNKIRTRVHELVNTVNGFFRSMNVDASLANLEV  LEBET_MACLE  -QQRFEPRYIELVIVADHAMVTKYNGDLAAITTWVHQLVNNINGFYRDLNVHITLSAVEV  ACLF2_AGKLA  -QQGFPQRYVELVIVADHRMNTKYNGDSDKIRQWVHQIVNTINEIYRPLNIRFALVGLEI  HYRSR_CRORU  --QNLPQSYIELVVVADHRMFMKYNSDLNTIRTRVHEIVNFINEFYRSLNIRVSLTDLEI  HR2A_TRIFL  -QQRFPQRYIELAIVVDHGMYTKYSSNFKKIRKRVHQMVNNINEMYRPLNIAITLSLLDV  DISJ_BOTJA  -QRYDPYKYIEFFVVVDQGTVTKNNGDLDKIKARMYELANIVNEIFRYLYMHVALVGLEI  HRL2_LACMU  ----FSQKYIELVVVADHGMFTKYNGNLNTIRTRVHEIVNTLNGFYRSLNILISLTDLEI  ACUL2_AGKAC -VSTEQQRYMEIVIVVDHSMVKKYNGDSDKIKAWVYEMINTITESYRYLYIDIILSGLEI ACUTC_AGKAC ---PAPQTSIELFLIVDHSMYAKYNSNSSKITTTLKARVNIMNAIYSSLNLVITLSGIEM ACUTA_AGKAC -----FQRYMEIVIVVDHSMVKKYNGDSDSIKAWVYEMINTITESYSYLKIDISLSGLEI HRTD_CROAT -QQNLPQRYIELVVVADHRVFMKYNSDLNTIRTRVHEIVNFINGFYRSLNIHVSLTDLEI ::: s:s*: * : * : * s: : : : ADAM_CROAD  EFSDDSMGYYQKFLNQYKPQCILNKP  FIBR_AGKCO  LFSDCSKKDYQTFLTVNNPQCILNKP  ATROX_CROAT  EFSDDSMGYYQSFLKQYNPQ------HR2_TRIFL  LFSDCSKNDYQTFLTKYNPQCILNAP  NEUW_BOTNE  EFSDCSKDYYQTFLTNHNPQ------LEBET_MACLE  QFSDCSKNKYQTYLTNRNPQCILNQP  ACLF2_AGKLA  LFSDCSKKDYQTFLPVNNPQCILNKP  HYRSR_CRORU  EFSDASMRYYQKFLDQYKPQCILNKP  HR2A_TRIFL  LFSDCSKDYYQTFLTNSKPQCIINAP  DISJ_BOTJA  FFSNCSYIQCWDFIMNHNPECIINEP  HRL2_LACMU  EFSDCSKDYYQMFLTKRKPQCILNKP  ACUL2_AGKAC  YFSDCSYIQCWDYIMKENPPCILNKP  ACUTC_AGKAC  SFSDCSKHDYQSFLTIHKPQCLLN--ACUTA_AGKAC YFSDCSYIQCRDYIAKENPPCILN--HRTD_CROAT EFSDDSMHYYERFLKQYKPQCILNKP **: * ss s* both the hemorrhagic and nonhemorrhagic enzymes. However, in certain regions the nonhemorrhagic enzymes have high average homology and the alignment of fibrolase with the hemorrhagic enzymes has lower average homology (eg, amino acids 75-90). For most regions of the sequence, the average homology for fibrolase compared to the 5 nonhemorrhagic metzincins was higher (mean average homology [MAH] = 0.68 on a scale of 0-1) than the average homology of fibrolase compared to the 8 hemorrhagic enzymes (MAH = 0.57).
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By subtracting the average homology profile of the hemorrhagic metzincins from the average homology profile of the nonhemorrhagic metzincins, sequence regions that might be important in determining substrate specificity for each class of enzyme are apparent as positive peaks of differential average homology in Figure 2B . Two sections of high differential average homology were found in the quantitative homology analysis of these enzymes. Two predominately α-helical regions-63-90 and 179-193-of the protein, with the highest differential average homology (peaks > 0.2), lie on the same side, above and below the active site cleft as can be seen by the green sections of Figure 3 . In addition, the region containing a characteristic loop and 2 disulfides-150-176-has 3 peaks of high differential average homology. These are regions that surround the active site and might play a role in substrate recognition of the external surface of the fibrin molecule. Another region of high differential average homology lies at the N-terminus-8-19 and 30-37-and represents the second hydrophobic extended element of the parallel beta pleated sheet making up the core of the enzyme and a small section of the first alpha helix, respectively. We offer no speculation regarding the role of these structures in determining the differential activity of hemorrhagic versus nonhemorrhagic enzymes.
Adamalysin II is not hemorrhagic or fibrinolytic. As such we would not expect to see the same differential average homology profile when it is compared to the fibrinolytic and hemorrhagic enzymes. Therefore, as a control experiment, we calculated the differential average homology of adamalysin II compared to 8 hemorrhagic and all 6 nonhemorrhagic metzincins ( Figure 2C and 2D ). Adamalysin II shows very little difference between the average homology profile when hemorrhagic and nonhemorrhagic enzymes are compared ( Figure 2C ). The mean average homology for the 6 nonhemorrhagic metzincins (MAH = 0.65 on a scale of 0-1) was not significantly different than the mean average homology of the 8 hemorrhagic enzymes (MAH = 0.61). Figure 2D shows that the differential average homology profile shows no characteristic peaks of differential homology suggesting regions of the protein that are differentially common to either the fibrinolytic or the hemorrhagic metzincins. Figure 4 shows a close-up view of the putative active site of fibrolase. The purple zinc ion can be seen because it is coordinated with the 3 histidines directly below a bound water molecule. Presumably, polarization of the water helps with the removal of a proton from the water by GLU 144. Subsequent attack of the hydroxide ion on the carbonyl carbon of the lysine residue in the substrate peptide results in fibrin cleavage (52) . Fibrolase has been identified in multiple isoforms, 2 of which differ in the truncation of an amino terminal glutamine that has no effect on functionality of the molecule. Additionally, length of the free rotating amino and carboxy termini preclude these molecule ends from any interaction with the active site, thus minimizing the possibility that the termini play any part in catalytic action or substrate specificity.
DISCUSSION
The fibrolase sequence contains 6 cysteine residues. Experimentation has shown that the protein possesses no free sulfhydryls, therefore the protein has 3 disulfide bonds placing it in a different group than atrolysin and adamalysin (both of which only have 2 disulfides) on which the modeled structure is based. The position of 1 of the disulfides is unambiguous (C118-C198) and is retained across all members of the metzincin family. The disulfide bonding pattern of the remaining cysteine residues is more ambiguous. The enzyme structures on which fibrolase is modeled share the position of a disulfide bond between C158-C165. The nonhemorrhagic H 2 -proteinase from Trimeresurus flavoviridis, another member of the metzincin family whose crystal structure has recently been solved, shows strong homology to fibrolase with respect to positioning of the disulfide bonds. Kumasaka et al describe the solved crystal structure of the H 2 -proteinase, which shares 62% homology with fibrolase; this protein possesses 3 disulfide bonds (as does fibrolase), and the positions of the cysteine residues in H 2 -proteinase are identical to those found in fibrolase (31). The crystal structure of H 2 -proteinase unambiguously determined that the disulfide bonding pattern in a 3-disulfide containing metzincin pairs C158-C182 and C160-C165. A similar disulfide bonding pattern has also been observed for acutolysin A and C (28) . The bonding pattern in the modeled structure of fibrolase was minimized with the H 2 -proteinase disulfide pattern rather than retaining the disulfide bond observed in adamalysin. The minimum energy of the fibrolase structure with a 3-disulfide bonding pattern compared to the alternate adamalysin bonding pattern did not differ significantly. For the final fibrolase model, the H 2 -proteinase disulfide pattern was selected.
The overall structure of fibrolase when compared to adamalysin and atrolysin is obviously similar as a result of the method of fibrolase model construction. Details of the structure differ in key secondary structural elements that may play important roles in the substrate specificity. By calculating the differential average homology profile, we have identified regions of fibrolase that are highly conserved in the nonhemorrhagic metzincins and poorly conserved in the hemorrhagic metzincins. These regions of fibrolase are located on the surface of the enzyme above and below the active site cleft and may play a role in recognition of the surface of fibrinogen as opposed to the basement membrane proteins that are substrates of the hemorrhagic metzincins. The sequence of the cleavage peptide modeled with the fibrolase molecule is based on the sequence of the natural substrate. The cleavage of the large molecule substrate will require that only the K and L positions be available for cleavage, but the positioning of the macromolecular substrate is directed by residues outside the active site. This line of thought is supported by the apparent substrate selectivity toward the large molecule substrates whereas octapeptide substrates require only an XLeu (or Phe) bond (Swenson et al, in preparation). The apparent selectivity of the useful substrate is not based on an inability to cleave bonds only on the large molecule's ability to effectively present the peptide bond for cleavage.
Adamalysin does not share substrate specificity with either the hemorrhagic or nonhemorrhagic metzincins. The mean differential average homology (MDAH) for adamalysin compared to the other 2 classes of metzincins is very close to zero (MDAH = 0.04), whereas the mean differential average homology for fibrolase was greater than zero (MDAH = 0.11). This comparison supports the significance of the differential average homology profile as a tool for analysis of sequence regions that may play a role in distinguishing the activity of closely related protein families.
Additionally, modifications can be made to fibrolase that will affect its proteolytic activity to either make it a stronger or weaker agent depending on the need. Although this can be done through trial and error from an understanding of the primary structure, understanding the 3-dimensional structure will allow the determination of more specific targets for modification and change. Fibrolase shares a number of sequence and structural features with enzymes that possess vastly different activities. The difference that determines substrate specificity in either sequence or structure can be exploited to construct a more useful agent.
To create a more effective fibrinolytic enzyme and to target the enzyme to platelet-rich thrombi, thereby decreasing the potential for rethrombosis, a chimeric derivative of fibrolase has been produced (23, 24) . Covalent modification of the native protein through heterobifunctional crosslinking agents has allowed for the adduction of an RGD-like peptide to the surface of fibrolase. The stoichiometry of covalently adducted heterobifunctional crosslinker S-GMBS (N-(γ -maleimidobutyryloxy) sulfosuccinimide ester, Pierce Chemical, Rockford, IL) to fibrolase indicates that only 1 of the 7 lysine residues is the predominant site for adduction. The site of peptide attachment was determined to be a single lysine (LYS-184) residue. Lysine 185 could only be adducted by exposing the enzyme to the chemical modifying reagents for a much longer time. The effect on the overall structure of fibrolase caused by forming the peptide adduct was analyzed using the 3-dimensional model of fibrolase described here. Lysine 184, when adducted, positions the crosslinker and the RGD-like peptide distant from the active site of the enzyme. Although our model of fibrolase indicates that all of the lysine residues lie on the surface of the molecule (and with extended incubation, all of the lysines are capable of reacting with the S-GMBS), the lysine at position 184 is shown to be the most rapidly adducted position by S-GMBS. From the structural model of fibrolase, the predicted position of this lysine is on the helix closest to the C-terminal end of the protein. This part of fibrolase is close to the 2 loops that are held in position by 2 disulfide bonds, making it a fairly rigid site for reaction. LYS-185 may not be as reactive as LYS-184 because it is able to form a salt bridge with ASP-181. In addition, the predicted positioning of lysine 184 as being distant from the active site correlates with our observations, which show essentially no loss of intrinsic fibrinolytic activity in the chimeric molecule.
CONCLUSIONS
Thrombotic disease is one of the chief causes of mortality in the United States. Development of more effective therapeutic approaches for treating occlusive thrombotic disease is a first step in decreasing deaths from this disease. Fibrolase has the potential to treat medically relevant blood clots in a way other drugs are unable to-through direct thrombus degradation. Understanding the mechanism and possible reasons for enzymatic selectivity will further the development of drugs, with the potential to make a major impact against this disease. Structural analysis of drugs can lead to better drugs through by forming heterofunctional agents and adding excipients (such as Polyethylene Glycol, PEG) to impart protection from immune recognition. Ongoing design efforts such as those explored here will create stronger, more stable pharmaceutical agents; the information gained from the model-building process has proved invaluable.
